vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Fastly, Inc. (FSLY). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $172.6M, roughly 1.0× Fastly, Inc.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -9.0%, a 8.3% gap on every dollar of revenue. On growth, Fastly, Inc. posted the faster year-over-year revenue change (22.8% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $12.2M). Over the past eight quarters, Fastly, Inc.'s revenue compounded faster (13.7% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Fastly, Inc. is an American company based in San Francisco, which describes itself as a cloud computing company. Fastly provides content delivery network services, image optimization, and load balancing services. Fastly's cloud security services include denial-of-service attack protection, bot mitigation, and a web application firewall.
AVNS vs FSLY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $172.6M |
| Net Profit | $-1.3M | $-15.5M |
| Gross Margin | 47.5% | 61.4% |
| Operating Margin | 1.4% | -8.7% |
| Net Margin | -0.7% | -9.0% |
| Revenue YoY | 0.7% | 22.8% |
| Net Profit YoY | 99.7% | 52.9% |
| EPS (diluted) | $-0.02 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $172.6M | ||
| Q3 25 | $177.8M | $158.2M | ||
| Q2 25 | $175.0M | $148.7M | ||
| Q1 25 | $167.5M | $144.5M | ||
| Q4 24 | $179.6M | $140.6M | ||
| Q3 24 | $170.4M | $137.2M | ||
| Q2 24 | $171.7M | $132.4M | ||
| Q1 24 | $166.1M | $133.5M |
| Q4 25 | $-1.3M | $-15.5M | ||
| Q3 25 | $-1.4M | $-29.5M | ||
| Q2 25 | $-76.8M | $-37.5M | ||
| Q1 25 | $6.6M | $-39.1M | ||
| Q4 24 | $-397.3M | $-32.9M | ||
| Q3 24 | $4.3M | $-38.0M | ||
| Q2 24 | $1.8M | $-43.7M | ||
| Q1 24 | $-900.0K | $-43.4M |
| Q4 25 | 47.5% | 61.4% | ||
| Q3 25 | 48.4% | 58.4% | ||
| Q2 25 | 52.6% | 54.5% | ||
| Q1 25 | 53.6% | 53.2% | ||
| Q4 24 | 54.6% | 53.4% | ||
| Q3 24 | 54.5% | 54.5% | ||
| Q2 24 | 55.7% | 55.1% | ||
| Q1 24 | 57.1% | 54.8% |
| Q4 25 | 1.4% | -8.7% | ||
| Q3 25 | 0.1% | -18.2% | ||
| Q2 25 | -42.6% | -24.8% | ||
| Q1 25 | 6.1% | -26.4% | ||
| Q4 24 | -233.0% | -24.4% | ||
| Q3 24 | 7.0% | -29.6% | ||
| Q2 24 | 3.7% | -35.3% | ||
| Q1 24 | 2.4% | -34.6% |
| Q4 25 | -0.7% | -9.0% | ||
| Q3 25 | -0.8% | -18.6% | ||
| Q2 25 | -43.9% | -25.2% | ||
| Q1 25 | 3.9% | -27.1% | ||
| Q4 24 | -221.2% | -23.4% | ||
| Q3 24 | 2.5% | -27.7% | ||
| Q2 24 | 1.0% | -33.0% | ||
| Q1 24 | -0.5% | -32.5% |
| Q4 25 | $-0.02 | $-0.10 | ||
| Q3 25 | $-0.03 | $-0.20 | ||
| Q2 25 | $-1.66 | $-0.26 | ||
| Q1 25 | $0.14 | $-0.27 | ||
| Q4 24 | $-8.64 | $-0.23 | ||
| Q3 24 | $0.09 | $-0.27 | ||
| Q2 24 | $0.04 | $-0.32 | ||
| Q1 24 | $-0.02 | $-0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $361.8M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $929.6M |
| Total Assets | $1.1B | $1.5B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $361.8M | ||
| Q3 25 | $70.5M | $342.9M | ||
| Q2 25 | $90.3M | $321.2M | ||
| Q1 25 | $97.0M | $307.3M | ||
| Q4 24 | $107.7M | $295.9M | ||
| Q3 24 | $89.0M | $308.2M | ||
| Q2 24 | $92.2M | $311.8M | ||
| Q1 24 | $75.8M | $329.5M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $929.6M | ||
| Q3 25 | $778.0M | $937.0M | ||
| Q2 25 | $776.3M | $942.6M | ||
| Q1 25 | $839.4M | $957.0M | ||
| Q4 24 | $828.5M | $965.3M | ||
| Q3 24 | $1.2B | $969.5M | ||
| Q2 24 | $1.2B | $981.2M | ||
| Q1 24 | $1.2B | $991.8M |
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.7B | $1.5B | ||
| Q1 24 | $1.7B | $1.5B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $22.4M |
| Free Cash FlowOCF − Capex | $21.3M | $12.2M |
| FCF MarginFCF / Revenue | 11.8% | 7.1% |
| Capex IntensityCapex / Revenue | 3.8% | 5.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $22.4M | ||
| Q3 25 | $14.0M | $28.9M | ||
| Q2 25 | $6.8M | $25.8M | ||
| Q1 25 | $25.7M | $17.3M | ||
| Q4 24 | $57.9M | $5.2M | ||
| Q3 24 | $23.0M | $5.0M | ||
| Q2 24 | $27.8M | $-4.9M | ||
| Q1 24 | $-8.0M | $11.1M |
| Q4 25 | $21.3M | $12.2M | ||
| Q3 25 | $7.0M | $22.9M | ||
| Q2 25 | $-4.2M | $15.9M | ||
| Q1 25 | $19.0M | $14.7M | ||
| Q4 24 | $53.1M | $251.0K | ||
| Q3 24 | $20.0M | $3.0M | ||
| Q2 24 | $21.9M | $-6.7M | ||
| Q1 24 | $-12.1M | $9.5M |
| Q4 25 | 11.8% | 7.1% | ||
| Q3 25 | 3.9% | 14.5% | ||
| Q2 25 | -2.4% | 10.7% | ||
| Q1 25 | 11.3% | 10.2% | ||
| Q4 24 | 29.6% | 0.2% | ||
| Q3 24 | 11.7% | 2.2% | ||
| Q2 24 | 12.8% | -5.1% | ||
| Q1 24 | -7.3% | 7.1% |
| Q4 25 | 3.8% | 5.9% | ||
| Q3 25 | 3.9% | 3.8% | ||
| Q2 25 | 6.3% | 6.6% | ||
| Q1 25 | 4.0% | 1.8% | ||
| Q4 24 | 2.7% | 3.5% | ||
| Q3 24 | 1.8% | 1.5% | ||
| Q2 24 | 3.4% | 1.3% | ||
| Q1 24 | 2.5% | 1.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
FSLY
| Network Services | $130.8M | 76% |
| Security | $35.4M | 21% |
| Other | $6.4M | 4% |
